lipid-a and Lassa-Fever

lipid-a has been researched along with Lassa-Fever* in 1 studies

Other Studies

1 other study(ies) available for lipid-a and Lassa-Fever

Article	Year
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nature communications, 2018, 10-11, Volume: 9, Issue:1 Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is adjuvanted by a TLR-4 agonist (GLA-SE). LASSARAB elicits lasting humoral response against LASV and RABV in both mouse and guinea pig models, and it protects both guinea pigs and mice against LF. We also demonstrate a previously unexplored role for non-neutralizing LASV GPC-specific antibodies as a major mechanism of protection by LASSARAB against LF through antibody-dependent cellular functions. Overall, these findings demonstrate an effective inactivated LF vaccine and elucidate a novel humoral correlate of protection for LF. Topics: 3T3 Cells; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent Cell Cytotoxicity; Cell Membrane; Genetic Vectors; Glucosides; Glycoproteins; Guinea Pigs; Immunity, Humoral; Immunization; Immunoglobulin G; Lassa Fever; Lassa virus; Lipid A; Macrophages; Mice; Mice, Inbred C57BL; Rabies Vaccines; Receptors, IgG; Vaccines, Synthetic; Virion; Virulence	2018

Article

Year

Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.

Nature communications, 2018, 10-11, Volume: 9, Issue:1

Lassa fever (LF), caused by Lassa virus (LASV), is a viral hemorrhagic fever for which no approved vaccine or potent antiviral treatment is available. LF is a WHO priority disease and, together with rabies, a major health burden in West Africa. Here we present the development and characterization of an inactivated recombinant LASV and rabies vaccine candidate (LASSARAB) that expresses a codon-optimized LASV glycoprotein (coGPC) and is adjuvanted by a TLR-4 agonist (GLA-SE). LASSARAB elicits lasting humoral response against LASV and RABV in both mouse and guinea pig models, and it protects both guinea pigs and mice against LF. We also demonstrate a previously unexplored role for non-neutralizing LASV GPC-specific antibodies as a major mechanism of protection by LASSARAB against LF through antibody-dependent cellular functions. Overall, these findings demonstrate an effective inactivated LF vaccine and elucidate a novel humoral correlate of protection for LF.

Topics: 3T3 Cells; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent Cell Cytotoxicity; Cell Membrane; Genetic Vectors; Glucosides; Glycoproteins; Guinea Pigs; Immunity, Humoral; Immunization; Immunoglobulin G; Lassa Fever; Lassa virus; Lipid A; Macrophages; Mice; Mice, Inbred C57BL; Rabies Vaccines; Receptors, IgG; Vaccines, Synthetic; Virion; Virulence

2018